RxDoctor Payments Data

James McAleer, DO

Cardiovascular Disease · Colorado Springs, CONPI 1205364841

Payments from drug & device makers

$2,667in general payments, 2019–2025

Across 54 payments — averaging $49.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$896
  • Cardiovascular Systems Inc.$375
  • Boston Scientific$217
  • Shockwave Medical, Inc$173
  • Angiodynamics, Inc.$148
  • Cook Incorporated$141
  • plus $718 from 9 others

What the payments were for

  • Grants$1415%
  • Food & beverage$2,38990%
  • Education$1375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,667 in reported general payments places this provider in the 50th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$112,141
Medicare patients
827
Services billed
4,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$64,111
FarxigaDapagliflozin Propanediol16$19,765
JardianceEmpagliflozin11$15,974
Flecainide Acetate20$1,621
Metoprolol Succinate127$1,458
Potassium Chloride34$726
Rosuvastatin Calcium53$707
Atorvastatin Calcium67$630
Ezetimibe22$600
Amlodipine Besylate95$578
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$470
Furosemide81$427
Losartan Potassium49$409
Nitroglycerin38$363
Valsartan13$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$64,11145 claims
AstraZenecaFarxiga$124$19,76516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →